Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on March 17, 2025
Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
GlobeNewswire
·
March 17, 2025
JACKSON CENTER, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) partnered with Athena GTX on a profit-sharing agreement over a year ago. This enabled Halberd to utilize Athena’s expertise and experience in dealing with the federal …
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
·
March 17, 2025
- Dosed the first patient in the Phase 2 Elumina trial of VLS-01 (buccal film DMT) for patients with treatment-resistant depression; topline data anticipated in Q1’26 - Initiated a Phase 2 clinical trial of EMP-01 (oral R-MDMA) for patients with social …
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo
GlobeNewswire
·
March 17, 2025
New Analyses Related to Aficamten Expand on its Metabolism Pathways, Treatment Effect Associated with Combination Therapy with Disopyramide and Longer-Term Effect on Cardiac Structure and Function SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE …
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
GlobeNewswire
·
March 17, 2025
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement …
Tiziana Life Sciences to Present at the 37th Annual Roth Conference
GlobeNewswire
·
March 17, 2025
NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
ProKidney Reports Full Year 2024 Financial Results and Business Highlights
GlobeNewswire
·
March 17, 2025
Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140 million of equity to extend cash runway …
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
GlobeNewswire
·
March 17, 2025
SAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based triple drug frontline therapy to treat …
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
GlobeNewswire
·
March 17, 2025
–Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies– WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas …
Kraig Biocraft Laboratories Confirms Operations in Vietnam's Silk Production Hub, Lam Dong Province
GlobeNewswire
·
March 17, 2025
ANN ARBOR, Mich., March 17, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk manufacturing, is pleased to confirm it has established production operations in Lam Dong …
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
GlobeNewswire
·
March 17, 2025
sNDA submission based on results from Phase 3 DUPLEX and Phase 2 DUET studies of FILSPARI in FSGS If approved, FILSPARI could become the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure …
Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome
GlobeNewswire
·
March 17, 2025
Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. …
Microbix & ACPCC support efforts to eliminate cervical cancer in the Indo-Pacific
GlobeNewswire
·
March 17, 2025
MISSISSAUGA, Ontario and MELBOURNE, Australia, March 17, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, and the Australian Centre for the Prevention of Cervical …
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
March 17, 2025
WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that …
Spectral AI Announces Successful Results from its Burn Validation Study of the DeepView System
GlobeNewswire
·
March 17, 2025
DeepView® System outperforms burn physicians in identifying non-healing tissue Landmark Burn Validation Study, one of the largest in U.S. history, confirms DeepView’s performance Spectral AI plans FDA submission by mid-2025, targeting De Novo Clearance and …
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
GlobeNewswire
·
March 17, 2025
– Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – – Dr. Carlos Paya Nominated to Board of Directors – – New Executives Appointed to Leadership Team; …
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
GlobeNewswire
·
March 17, 2025
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström Macroglobulinemia First-in-class Bruton’s tyrosine kinase (BTK) degrader NX-5948 assigned nonproprietary name “bexobrutideg” in newly named …
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
GlobeNewswire
·
March 17, 2025
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy …
Global Transdermal Patch Market Size Transdermal Patches Clinical Trials Approved Patches Price Dosage Market Forecast 2030
GlobeNewswire
·
March 17, 2025
Delhi, March 17, 2025 (GLOBE NEWSWIRE) -- Global Transdermal Patch Market Opportunity, Patch Dosage, Price …
Bispecific Antibodies Market Size Approved Bispecific Antibody Sales Price Patent Market Forecast 2030
GlobeNewswire
·
March 17, 2025
Delhi, March 17, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity, Drug Dosage, Patent, Price, Sales …
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
GlobeNewswire
·
March 17, 2025
SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidated financial …